# Domain Expert Evaluation: Connectomics Hypotheses in Alzheimer's Disease Cognitive Decline
---
## 1. Hypotheses with Highest Translational Potential
### Tier 1 (Highest Priority)
**Hypothesis 2 (Highest Translation Potential): Hippocampal-Cortical Memory Circuit Disconnection**
This is the most translationally ready of the six domains for the following reasons:
- Structural disconnection between hippocampus, entorhinal cortex, and posteromedial parietal cortex is directly measurable with both DTI and high-resolution structural MRI
- The hippocampus is the primary site of earliest measurable atrophy (entorhinal cortex layer II, CA1) and provides the clearest sequence: measurable disconnection precedes measurable cognitive decline by 1-2 years in ADNI data
- Patient population fit is excellent: amnestic MCI populations with hippocampal disconnection are the exact populations where lecanemab and donanemab have demonstrated clinical benefit (TRAILBLAZER-ALZ 2, CLARITY-AD), and connectivity metrics can serve as enrichment biomarkers
- Existing clinical infrastructure: hippocampal volume on MRI (FDA-qualified) and connectivity metrics using clinical 3T scanners are already standardized
**Hypothesis 5: Sleep-Wake Cycle Disruption and Thalamic Connectivity**
This has high translation potential for distinct reasons:
- The sleep-wake cycle offers a modifiable risk factor that may precede detectable neurodegeneration by years
- Suvorexant (orexin receptor antagonist) is FDA-approved for insomnia in AD patients; mechanistic data suggest it may enhance N3 slow-wave sleep-dependent glymphatic clearance
- A Phase 2 trial (NCT04639047) testing suvorexant in MCI/AD with amyloid biomarker endpoints provides a near-term regulatory pathway
- Thalamic connectivity disruption is measurable with resting-state fMRI and is particularly relevant because the thalamus functions as a relay hub—making it both a contributor to and detector of distributed connectivity failure
### Tier 2 (Important but requiring more validation)
**Hypothesis 4: Functional Hyperconnectivity as Compensatory Mechanism vs. Early Pathology Marker**
The distinction between compensatory hyperconnectivity and early dysconnectivity is mechanistically important but clinically premature. However, this domain has value as an enrichment strategy: subjects showing hyperconnectivity in DMN regions despite amyloid positivity may represent a subpopulation with greater synaptic reserve, potentially explaining heterogeneity in anti-amyloid antibody response.
---
## 2. Clinical Evidence, Safety, and Patient Population by Hypothesis
### Hypothesis 2: Hippocampal-Cortical Disconnection
| Dimension | Assessment |
|-----------|------------|
| **Clinical Evidence** | Strong. ADNI longitudinal data (n>1,000, 10+ year follow-up) consistently shows that ERC-CA1 structural connectivity loss predicts MCI-to-AD conversion better than hippocampal volume alone. Functional disconnection measured by rs-fMRI correlates with Word List Recall performance (r≈0.45). Tau PET (Braak